SCHEMBL3380108

SCHEMBL3380108

CN(CC1CC(Oc2cccc(CN3CCCC3)c2Cl)C1)C(=O)Nc1ccc(Cl)cc1

nearest known ligand 0.43

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
HRH3 Q9Y5N1 1/20 0.43
KDM4E B2RXH2 2/20 0.38
MAPT P10636 2/20 0.38
LMNA P02545 1/20 0.38
HPGD P15428 1/20 0.38
CCR1 P32246 2/20 0.37
EPHX2 P34913 2/20 0.37
ALDH1A1 P00352 3/20 0.37
TP53 P04637 1/20 0.37
POLB P06746 1/20 0.37
P2RX7 Q99572 1/20 0.37
CHRM1 P11229 3/20 0.36
HTR2A P28223 3/20 0.36
MCHR1 Q99705 3/20 0.36
GAA P10253 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
ACKR3 P25106 1/20 0.36
ACHE P22303 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3377282 0.95 HRH3 (0.43) HRH3KDM4EMAPTHPGDCCR1
SCHEMBL3381102 0.94 HRH3 (0.42) HRH3KDM4EMAPTLMNACCR1
SCHEMBL3376421 0.94 HRH3 (0.44) HRH3ALDH1A1POLBP2RX7
SCHEMBL3377799 0.92 HRH3 (0.41) HRH3KDM4EMAPTLMNACCR1
SCHEMBL3378690 0.91 MEN1 (0.42) HRH3KDM4EMAPTLMNAHPGD
SCHEMBL3380398 0.91 DNMT1 (0.43) HRH3CCR1EPHX2
SCHEMBL3379649 0.90 HRH3 (0.41) HRH3KDM4EMAPTLMNAALDH1A1
SCHEMBL3376040 0.90 HRH3 (0.43) HRH3KDM4EMAPTLMNAALDH1A1
SCHEMBL3377304 0.90 HRH3 (0.42) HRH3KDM4EMAPTLMNAALDH1A1
SCHEMBL3379936 0.89 HRH3 (0.41) HRH3KDM4EMAPTALDH1A1POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1899296-B1 HISTAMINE-3 RECEPTOR ANTAGONISTS PFIZER PROD INC (US) 2010-11-17 EP claimed
US-7812040-B2 such as 3-(3-Acetyl-phenyl)-1-[3-(3-chloro-4-pyrrolidin-1-ylmethyl-phenoxy)-cyclobutylmethyl]-1-methyl-urea, used for the treatment of , schizophrenia, Alzheimer's disease, attention-deficit hyperactivity disorder, hypotension, allergies, cardiovascular, gastrointestinal and psychological disorders PFIZER INC. (US) 2010-10-12 US claimed
US-20090131433-A1 HISTAMINE-3 RECEPTOR ANTAGONISTS PFIZER INC. (US) 2009-05-21 US claimed
EP-1899296-B1 HISTAMINE-3 RECEPTOR ANTAGONISTS PFIZER PROD INC (US) 2010-11-17 EP disclosed
US-7812040-B2 such as 3-(3-Acetyl-phenyl)-1-[3-(3-chloro-4-pyrrolidin-1-ylmethyl-phenoxy)-cyclobutylmethyl]-1-methyl-urea, used for the treatment of , schizophrenia, Alzheimer's disease, attention-deficit hyperactivity disorder, hypotension, allergies, cardiovascular, gastrointestinal and psychological disorders PFIZER INC. (US) 2010-10-12 US disclosed
US-20090131433-A1 HISTAMINE-3 RECEPTOR ANTAGONISTS PFIZER INC. (US) 2009-05-21 US disclosed
EP-1899296-A1 HISTAMINE-3 RECEPTOR ANTAGONISTS Pfizer Products Incorporated (US) 2008-03-19 EP disclosed
WO-2006136924-A1 HISTAMINE-3 RECEPTOR ANTAGONISTS PFIZER PRODUCTS INC. (US) 2006-12-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090131433-A1 HISTAMINE-3 RECEPTOR ANTAGONISTS HRH3, HRH4, HRH2 HRH3 1/4885KDM4E 3381/4885MAPT 320/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.